Denali Advisors’s Enliven Therapeutics ELVN Stock Holding History

Denali Advisors’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-9,900	Closed	-$202K	–	491
2023 Q2	$202K	Buy	+9,900	New	+$200K	0.07%	213

Other funds holding ELVN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Denali Advisors's ELVN Position: Q3 2023 in Review

Denali Advisors sold out of Enliven Therapeutics (ELVN) in Q3 2023, closing a stake of 9,900 shares — an estimated $202K sold.

Denali Advisors first reported a position in ELVN in Q2 2023 and held it in 1 quarter. The position peaked at $202K in Q2 2023. 61 funds tracked by Wall St. Rank hold ELVN as of Q3 2023.

Denali Advisors reported no remaining Enliven Therapeutics position as of Q3 2023 after selling out during the quarter.
Denali Advisors sold 9,900 Enliven Therapeutics shares in Q3 2023, an estimated $202K.
Denali Advisors first reported a position in Enliven Therapeutics in Q2 2023 and held it in 1 quarter.
Denali Advisors's Enliven Therapeutics position peaked at $202K in Q2 2023.
61 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2023.

Based on Denali Advisors's 13F filing for Q3 2023, filed 19 Oct 2023.